Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ISRIB and Lemairamin — mechanism, side effects, legal status, and pricing.
ISRIB is a non-peptide small-molecule eIF2B activator (bis-chlorophenoxyacetamide-cyclohexane class) that antagonizes the integrated stress response (ISR) by stabilizing the eIF2B guanine-nucleotide exchange factor complex. It is not an approved drug and has no completed human clinical trials or validated human safety or efficacy data. Chemically distinct eIF2B-activator analogs (DNL343, ABBV-CLS-7262) have reached human trials, but DNL343 missed primary endpoints in a Phase 2/3 ALS trial (January 2025). ISRIB is sold by reagent suppliers for research use only.
Lemairamin is a non-peptide small-molecule cinnamamide alkaloid (N-phenethyl cinnamide) natural product, not approved for human use in any jurisdiction. All available data are preclinical (rodent, zebrafish, C. elegans, in vitro, and computational). It is sold exclusively as an unregulated 'research chemical' explicitly labeled 'not for human consumption'; quality, purity, and identity are not independently verified by any regulatory body. No human clinical trials, pharmacokinetic studies, or safety data exist.
ISRIB
Lemairamin
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ISRIB
Lemairamin
No pricing data yet.
Check Lemairamin prices →COA corpus from Disclosed Labs — independently tested batches only.
ISRIB
1
COAs
99.8%
Avg purity
1
Labs
Lemairamin
2
COAs
99.8%
Avg purity
2
Labs
No completed or published human clinical trials of ISRIB itself exist; it has no validated human pharmacokinetic, safety, or efficacy data. In mice, systemic ISRIB enhanced spatial and fear-associated long-term memory in healthy animals, reversed hippocampus-dependent spatial-learning and working-memory deficits weeks after traumatic brain injury, and reset elevated ISR activity in aged (18–24 month) mice, reversing age-related spatial-memory decline with a brief 3-day dosing course. In prion-disease transgenic mice, ISRIB partially restored protein synthesis and prevented neurodegeneration without the pancreatic exocrine toxicity seen with PERK-inhibitor approaches. In vitro and in a patient-derived xenograft mouse model, ISRIB combined with imatinib attenuated RAS/RAF/MAPK and STAT5 signaling and eliminated therapy-resistant chronic myeloid leukemia cells.
Key references
No human data exist. No completed or registered human clinical trials were located on ClinicalTrials.gov, and no PubMed-indexed human pharmacokinetic, safety, or efficacy studies exist. All available data are preclinical: In transgenic Alzheimer's mice, gx-50 disassembled Aβ oligomers, decreased cortical Aβ accumulation, inhibited Aβ-induced neuronal apoptosis and calcium toxicity, improved Morris water maze performance, and was reported to cross the blood-brain barrier (Tang et al. 2013). In mouse and rat pain models (formalin tonic, neuropathic, bone-cancer pain), subcutaneous and intrathecal lemairamin dose-dependently reduced pain hypersensitivity/mechanical allodynia without evident tolerance, linked to spinal α7 nAChR activation and downstream IL-10/β-endorphin release (Wang et al. 2020). Murine microglial cell cultures showed gx-50 activation of α7 nAChR engaged JAK2/STAT3 and PI3K/AKT signaling to suppress pro-inflammatory cytokine secretion (Shi et al. 2016). Zebrafish DSS-induced colitis models showed lemairamin attenuated intestinal inflammation via Akt signaling (2024). C. elegans studies reported WGX-50 promoted markers of healthy ageing (daf-16/skn-1 longevity genes, 2025).
ISRIB and Lemairamin are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs